ADCT-502

N/A

Report date: 2024/02/05 13:59:25

Base Information

Drug NameADCT-502

Drug Alias Nameengineered trastuzumab + pyrrolobenzodiazepine dimer cytotoxinADCT-502

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PBD dimer SG3199 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-HER2DNA cross linking agents

TargetsReceptor protein-tyrosine kinase erbB-2DNA

Therapy Area/IndicationsUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungStomach Neoplasms +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCancer Research Technology Adc Therapeutics Sa

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAdc Therapeutics Sa

Active IndicationsN/A

Inactive IndicationsUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungStomach Neoplasms +[5]

Other Information

ATC CodeN/A